MannKind Corporation develops patient-focused drug therapies and innovative technology solutions.
We specialize in innovative technologies with proven ease-of-use and patient acceptance.
Needle-free, self-administered Inhalation Treatment Systems for both chronic and acute diseases.
Our Technosphere® technology can accommodate a wide variety of APIs required by specific drug therapies.
MannKind Corporation (NASDAQ and TASE: MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. More
2017 Annual Meeting of Stockholders
held on May 18, 2017.
|May 10, 2017||MannKind Corporation Reports 2017 First Quarter Financial Results… More|
|May 04, 2017||MannKind and One Drop to collaborate on delivering better health outcomes for people with diabetes… More|
|Apr 28, 2017||MannKind Corporation to Hold 2017 First Quarter Financial Results Conference Call on May 10, 2017… More|